Increasing Demand for Nutraceutical Products Drives the EMEA Solid Oral Nutraceuticals Excipients Market

Solid oral nutraceutical excipients are non-active substances strategically incorporated into the formulation of nutritional products in dosage forms, such as tablets or capsules, to fulfill various functional roles. These excipients play a pivotal role in the overall product development process, contributing to the final nutraceutical product's physical attributes, manufacturability, and performance. Binders, for instance, are used to provide cohesiveness to the formulation, facilitating the compression of ingredients into tablets. Conversely, diluents increase the bulk of the formulation, ensuring consistent dosage and aiding in the manufacturing process. Disintegrants are another category of excipients designed to promote the break-up of the tablet or capsule upon ingestion, facilitating the release of active ingredients for optimal absorption.These excipients collectively contribute to solid oral nutraceuticals' stability, bioavailability, and overall efficacy, allowing for the successful production of high-quality products that meet regulatory requirements and consumer expectations.

Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/emea-solid-oral-nutraceutical-excipient-market

Data Bridge Market Research analyzes that the EMEA Solid Oral Nutraceuticals Excipients Market is expected to grow at a CAGR of 6.6% in the forecast period of 2024 to 2031 and is expected to reach USD 443,498.11 million by 2031. The coatings segment is projected to propel the market growth due to the rising adoption and demand of nutraceutical products.

Key Findings of the Study

Rising Advancements in Nutraceutical Excipients

The need for excipients that can help formulate and deliver these nutraceuticals more effectively is growing at the same time that this research is expanding. In nutraceutical products, excipients play a crucial role in guaranteeing the stability, bioavailability, and efficacy of active ingredients. Their role is crucial in converting research results into feasible and commercially viable formulations. Nutraceuticals are gaining fresh insights into their health-promoting qualities through scientific studies, clinical trials, and ongoing research endeavors focused on determining their efficacy, safety, and possible applications.

The developments address the changing requirements of the nutraceutical sector and are typified by breakthroughs in excipient formulations and technologies. Manufacturers are investing in R&D to provide excipients for oral nutraceutical formulations that offer greater functionality, higher bioavailability, and better stability for active ingredients. This ongoing innovation improves the end products' quality and effectiveness by addressing issues with the efficient distribution of delicate or poorly soluble nutraceutical components.

Increased research efforts also lead to the discovery of new components and combinations, which fuels the need for excipients that support these developments. The need for excipients that help with the efficient formulation and delivery of these nutraceuticals is growing as the body of research on the subject grows. Furthermore, developments in excipient technology make it possible to create formulations that satisfy a range of consumer preferences by satisfying specific needs such as controlled release, taste masking, or enhanced absorption. The market is growing because of new excipients that guarantee improved compatibility with diverse active ingredients and production processes. This creates a landscape where products are more differentiated from one another and perform better.

Report Scope and Market Segmentation

Segment Analysis

The EMEA solid oral nutraceutical excipient market is segmented into five notable segments based on functionality, formulation, end product, excipient source, and distribution channel.

• On the basis of functionality, the market is segmented into binders, fillers & diluents, suspension & viscosity agents, coatings, disintegrants, and others

In 2024, the coatings segment is expected to dominate the market

In 2024, the coatings segment is expected to dominate the market with a market share of 31.81% due to its pivotal role in improving the taste, stability, and visual appeal of nutraceutical products, ensuring enhanced patient compliance and overall consumer acceptance.

• On the basis of formulation, the market is segmented into tablets, capsules, gummies, and others

In 2024, the tablets segment is expected to dominate the market

In 2024, the tablets segment is expected to dominate the market with a market share of 35.01% due to their convenience, ease of manufacturing, and precise dosage control, making them a preferred and widely accepted solid oral dosage form for nutraceutical products.

• On the basis of end product, the market is segmented into probiotics, prebiotics, protein and amino acid supplements, vitamin supplements, mineral supplements, omega-3 supplements, and other supplements. In 2024, the vitamin supplements segment is expected to dominate the market with a market share of 27.57%
• On the basis of excipient source, the market is segmented into synthetic and natural. In 2024, the natural segment is expected to dominate the market with a market share of 59.64%
• On the basis of distribution channel, the market is segmented into distribution channel, the market is segmented into direct tender, retail sales, and others. In 2024, the direct tender segment is expected to dominate the market with a market share of 46.60%

Major Players

Data Bridge Market Research analyzes BASF Corporation (Germany), DuPont (U.S.), Cargill, Incorporated (U.S.), Omya (Switzerland), and Kerry Group plc (Ireland) as the major market players of the EMEA solid oral nutraceuticals excipients market.

Market Development

• In October 2023, Ashland’s new bioresorbable generation platform, the organization, will be introducing Viatel Ultrapure, a high-purity bioresorbable polymer. This line extension gives you stepped forward balance for touchy drug compounds and longer, extra-regular drug launch profiles in Long-Appearing Injectables and Implants (LAII). These polymers additionally have wider software in dermal fillers, regenerative remedy scaffolds, and degradable clinical devices. This will help the company to expand its business in the life sciences segment
• In July 2023, Evonik Industries AG and Heraeus Precious Metals will increase the variety of services that both businesses offer for Highly Powerful Active Pharmaceutical Ingredients (HPAPIs). By combining the unique HPAPI capabilities of both businesses, the collaboration offers clients a fully integrated solution that spans pre-clinical research through commercial manufacturing
• In July 2023, strengthened its partnership with Solvay for the EMEA's advanced materials & additives market. The expansion of the partnership with Solvay is aligned with Azelis's strategy to grow organically with its partners and the focus on the strategic drivers in sustainability and innovation. This partnership allows azelis to offer its customers a broader range of high-performance solutions, enhancing their competitiveness and enabling them to meet evolving market demands for lightweight, energy-efficient, and sustainable materials. This further strengthens Azelis's dedication to promoting sustainability and driving innovation across diverse sectors
• In April 2023, Roquette Freres formally opened their brand-new Pharmaceutical Innovation Centre in the center of the Northeast pharmaceutical corridor of the United States, close to Philadelphia, Pennsylvania. The facility serves as an incubator for applied scientific innovation, focusing on drug delivery methods, nutraceutical APIs, oral dosage forms, and innovative pharmaceutical components. This has aided in the business expansion of the corporation

Regional Analysis

Geographically, the countries covered in the EMEA solid oral nutraceuticals excipients market report are Germany, Italy, U.K., France, Spain, Belgium, Netherlands, Russia, Switzerland, Turkey, rest of Europe, South Africa, Saudi Arabia, U.A.E., Algeria, Oman, Kuwait, and rest of Middle East and Africa.

As per Data Bridge Market Research analysis:

The Europe is estimated to be the dominant and fastest growing region in the EMEA solid oral nutraceuticals excipients market.

Europe is expected to dominate the market owing to the higher level of investments by manufacturers and the increasing advancement in expectations. Europe will continue to dominate the market in terms of market share and revenue and flourish its dominance during the forecast period. This is due to the growing adoption and demand for nutraceutical products. In addition, the growing health awareness among the population is expected to propel the market growth in this region.

For more detailed information about the EMEA solid oral nutraceuticals excipients market report, click here – https://www.databridgemarketresearch.com/fr/reports/emea-solid-oral-nutraceutical-excipient-market